Results 11 to 20 of about 50 (49)
Modifying dolutegravir to PrEPare for long life
Communications Biology, 2022 Anti-retroviral therapy with drugs like dolutegravir is a powerful tool in both the treatment and prevention of HIV, but is limited by strict adherence to a daily therapeutic regimen. In a recent study, Deodhar, Sillman, and colleagues developed a dolutegravir prodrug that offers long-lasting protection against HIV infection, with the potential to ...
openaire +3 more sources
Quantitative evaluation of the antiretroviral efficacy of dolutegravir [PDF]
JCI Insight, 2016 The second-generation HIV-1 integrase strand transfer inhibitor (InSTI) dolutegravir (DTG) has had a major impact on the treatment of HIV-1 infection. Here we describe important but previously undetermined pharmacodynamic parameters for DTG. We show that the dose-response curve slope, which indicates cooperativity and is a major determinant of ...
Robert F. Siliciano +2 more
openaire +2 more sources
The promise of paediatric dolutegravir [PDF]
Journal of the International AIDS Society, 2021 Rachel Golin +5 more
openaire +2 more sources
Dolutegravir drug-drug interactions
South African Medical Journal, 2022 Dolutegravir is neither an inducer nor an inhibitor of metabolising enzymes, and it therefore has a low propensity to act as a perpetrator of drug-drug interactions. Clinically significant decreases in dolutegravir exposure occur when it is co-administered with strong inducers (e.g.
Mondleki, E, Maartens, G
openaire +3 more sources
The role of dolutegravir in the management of HIV infections
Infection and Drug Resistance, 2015 Dolutegravir is the most recent integrase strand transfer inhibitor approved for HIV-1 infection in both treatment-naïve and experienced patients. As a tricyclic carbamoyl pyridone analog, dolutegravir is rapidly absorbed and distributes through the cerebrospinal fluid.
Staci M. Lockhart +3 more
openaire +5 more sources
Open Forum Infectious DiseasesAbstract Dolutegravir resistance is emerging in routine clinical contexts in southern Africa, primarily in patients with prior treatment experience failing dolutegravir-based antiretroviral therapy (ART). This potential issue was raised by The Nucleosides and Darunavir/Dolutegravir in Africa trial that compared dolutegravir and boosted ...
Richard A Murphy +5 more
openaire +2 more sources
Dolutegravir and rat whole embryo culture [PDF]
Birth Defects Research, 2021 Jennifer Jao +7 more
openaire +4 more sources
Adult dolutegravir doses in children
The Lancet HIV, 2020 Helena Rabie, Lisa Frigati
openaire +3 more sources
Resistance to Dolutegravir—A Chink in the Armor? [PDF]
The Journal of Infectious Diseases, 2018 openaire +3 more sources
Dolutegravir-associated hyperglycaemia in patients with HIV [PDF]
The Lancet HIV, 2020 Eva Laker +8 more
openaire +2 more sources